AVR 0.73% $15.04 anteris technologies ltd

Ann: HSV-2 Phase IIa Results Investor Webinar, page-151

  1. 839 Posts.
    lightbulb Created with Sketch. 41
    A couple of things I would like to know from this data is.

    1 - will there be a chance to test alternative delivery methods or additional boosters.
    2- Is there evidence that some form of cross protection for HSV-1 becomes known.
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.